<DOC>
	<DOCNO>NCT00089323</DOCNO>
	<brief_summary>RATIONALE : Diagnostic procedure detect tumor cell bone marrow may help doctor predict disease recurrence plan effective treatment . PURPOSE : This clinical trial study well diagnostic procedure work detect tumor cell bone marrow patient undergone surgery stage I , stage II , stage IIIA breast cancer .</brief_summary>
	<brief_title>Diagnostic Procedures Detecting Tumor Cells Bone Marrow Patients Undergoing Surgery Stage I , Stage II , Stage IIIA Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine relative risk death associate presence tumor cell bone marrow patient stage I , II , IIIA breast cancer undergo surgery bone marrow analysis use multicolor fluorescence immunocytochemistry bright field immunocytochemistry . Secondary - Compare multicolor fluorescence immunocytochemistry v bright field immunocytochemistry detection bone marrow micrometastases patient . OUTLINE : This multicenter study . Patients undergo bone marrow aspiration surgical resection primary tumor . Bone marrow cell tumor sample analyze use bright field immunocytochemistry multicolor fluorescence immunocytochemistry . Patients follow every 12 month 10 year . PROJECTED ACCRUAL : A total 1,634 patient accrue study within 3 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Inclusion criterion Histologic diagnosis invasive adenocarcinoma breast diagnose core , incisional , excisional biopsy . All follow stag criterion must meet : Primary tumor must operable staged cT13 clinical evaluation . Ipsilateral node must cN01 clinical evaluation . No evidence metastatic disease ( M0 ) . Exclusion criterion : Patients history breast malignancy include DCIS ( patient history Lobular Carcinoma Situ ( LCIS ) eligible ) . Treatment include radiation therapy , chemotherapy , and/or hormonal therapy administer currently diagnose breast cancer prior study entry . The exception hormonal therapy , may give total 28 day diagnosis study entry . Patients receive preoperative chemotherapy . Bilateral malignancy ( include DCIS ) . Other nonbreast malignancy unless patient consider diseasefree 5 year study entry deem physician low risk recurrence . Patients follow cancer eligible diagnose treat within past 5 year : carcinoma situ cervix , melanoma situ , colon carcinoma situ , basal cell squamous cell carcinoma skin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>stage IA breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>male breast cancer</keyword>
	<keyword>stage IB breast cancer</keyword>
</DOC>